ADAKVEO (crizanlizumab): revocation of EU marketing authorisation due to lack of therapeutic efficacy

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Adakveo
Active substance
Crizanlizumab
Therapeutic area (MeSH)
Anemia, Sickle Cell
Procedure number
EMEA/H/A-20/1525/C/4874/0013
Regulatory outcome
Revocation
DHPC type
  • Lack of effect
  • Referral - Article 20 procedure
Human ATC code
B06AX01
Dissemination date
15/06/2023

How useful was this page?

Add your rating